Biophytis S.A.
ISIN: FR0012816825 | Ticker: ALBPS | LEI: 9695008GIE061NBGU106
Country: France
Biophytis SA (www.biophytis.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, Biophytis has begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical needs.
Specifically, the company is advancing two proprietary drug candidates into mid-stage clinical testing this year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD).
The business model of BIOPHYTIS is to ensure the conduct of the project until clinical activity in the patient is proven, then to license the technologies in order to continue the development in partnership with a pharmaceutical laboratory.
The company was founded in partnership with researchers at the UPMC (Pierre and Marie Curie University) and collaborates with scientists at the Institute of Myology, and the Vision Institute
2006
Served areaWorldwide
Headquarters14 Avenue de l'Opéra, 75001 Paris – France
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 22.11.23 | None | Other | Buy | EUR 79,365.99 |
| 16.12.20 | None | Other | Sell | EUR 499,000.00 |
| 16.12.20 | None | Other | Other | EUR 0.00 |
| 30.04.20 | None | Other | Other | EUR 177,342.06 |
FR0012816825
LEI9695008GIE061NBGU106
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.